CV Sciences 3Q 2026: Revenue $3.03M, EPS ($0.00) — 10-Q Summary

CV Sciences reported 3Q 2026 revenue of $3.03M, down 7% YoY, with net loss narrowing to $93K. Sales volume and prices declined due to state regulations and higher discounts, but gross margin improved to 50%. New products contributed 48.4% of revenue. A legal settlement gain of $500K also impacted results.

Original reporting
Published Nov 13, 2026, 11:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 11:20 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
CV Sciences 3Q 2026: Revenue $3.03M, EPS ($0.00) — 10-Q Summary — source image
Decision brief

The 30-second read

$CVSINeutralLow
01

Why it matters

The earnings release provides the first public numbers for the quarter, offering fresh data for traders.

02

Market read

Micro‑cap earnings with limited market impact; primarily relevant to niche investors.

03

What to watch

Potential upside from new product launches accounting for 48% of revenue.

Relevance 6/10Novelty 5/10Timing: after‑hours release

Background

CV Sciences filed its Q3 2026 10‑Q, reporting modest revenue decline and loss improvement.

Company-level read

Ticker impact

$CVSINeutralMedium confidence
Context

Q3 2026 10-Q shows revenue down 7% YoY to $3.03M and net loss narrowing, with a $500K legal settlement gain.

Expected impact

likely modest pressure as investors price in lower revenue and modest loss narrowing.

Evidence & confidence

Micro‑cap earnings with small absolute numbers; market reaction typically muted.

Market effects

Limited impact on the broader hemp‑derived products sector.

Minimal effect on U.S. markets given the company's small size.

Negligible.

Counterpoint

If the settlement gain signals resolution of legal risk, the stock could rebound despite revenue decline.

Key entities

  • CV Sciences, Inc.

    Micro‑cap hemp‑derived product manufacturer.

Related articles

$CVSIMed

CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results

CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CV Sciences, Inc. Reports Third Quarter-End 2026 Financial Results San Diego, CA - November 12, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp ex

$CVSIMed

CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results

CV Sciences, Inc. (CVSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CV Sciences, Inc. Reports Second Quarter-End 2026 Financial Results San Diego, CA - August 13, 2026 (ACCESS Newswire) - CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent consumer wellness company specializing in hemp ext

$SLNHMed

Soluna Q3 Earnings Call Highlights

Soluna reported a Q3 gross loss of $1.9M, impacted by $3M in wind turbine repairs. Revenue was $12.4M, with mining revenue down 33%. The company has $109.3M in cash and $7.7M in debt post-repayment. Soluna formed a joint venture with Applied Digital for a 50MW facility, with closing expected by early December. Future AI projects may use 70-80% debt financing.

$NIUMed

Niu Tech (NIU) Q3 2026 Earnings Call Transcript

Niu Tech (NIU) reported Q3 2026 earnings, with total sales volume up 15.4% YoY to 534,057 units. Revenue was RMB 1.71 billion, up 1.2% YoY. China sales grew 8.6% YoY, while international sales surged 226%. Gross margin expanded to 18.0%. The company highlighted strong growth in electric motorcycles, which accounted for 56% of China sales, and strategic product launches.